-
-
-
-
-
-
-
Turning Point Therapeutics Inc. (TPTX) Announces FDA Clearance of IND Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified NSCLC
-
-
-
-
-
-
-
UPDATE: Stifel Starts Turning Point Therapeutics Inc. (TPTX) at Hold
-
-
-
-
-
-
-
Form S-1/A Turning Point Therapeuti
-
66,424 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

